177 related articles for article (PubMed ID: 7533452)
1. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group.
Lepor H
Urology; 1995 Mar; 45(3):406-13. PubMed ID: 7533452
[TBL] [Abstract][Full Text] [Related]
2. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
Roehrborn CG; Oesterling JE; Auerbach S; Kaplan SA; Lloyd LK; Milam DE; Padley RJ
Urology; 1996 Feb; 47(2):159-68. PubMed ID: 8607227
[TBL] [Abstract][Full Text] [Related]
3. The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia.
Lepor H; Meretyk S; Knapp-Maloney G
J Urol; 1992 Jun; 147(6):1554-7. PubMed ID: 1375659
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
Lepor H; Knapp-Maloney G; Wozniak-Petrofsky J
Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):392-7. PubMed ID: 2477339
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.
Lepor H; Auerbach S; Puras-Baez A; Narayan P; Soloway M; Lowe F; Moon T; Leifer G; Madsen P
J Urol; 1992 Nov; 148(5):1467-74. PubMed ID: 1279214
[TBL] [Abstract][Full Text] [Related]
6. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group.
Brawer MK; Adams G; Epstein H
Arch Fam Med; 1993 Sep; 2(9):929-35. PubMed ID: 7509243
[TBL] [Abstract][Full Text] [Related]
7. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia.
Tsujii T
Int J Urol; 2000 Jun; 7(6):199-205. PubMed ID: 10843450
[TBL] [Abstract][Full Text] [Related]
8. The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH.
Lepor H; Machi G
Prostate; 1992; 20(2):89-95. PubMed ID: 1372430
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
Elhilali MM; Ramsey EW; Barkin J; Casey RW; Boake RC; Beland G; Fradet Y; Trachtenberg J; Orovan WL; Schick E; Klotz LH
Urology; 1996 Mar; 47(3):335-42. PubMed ID: 8633398
[TBL] [Abstract][Full Text] [Related]
10. Terazosin for benign prostatic hyperplasia.
Wilt TJ; Howe RW; Rutks IR; MacDonald R
Cochrane Database Syst Rev; 2002; (4):CD003851. PubMed ID: 12519611
[TBL] [Abstract][Full Text] [Related]
11. A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia.
Lepor H; Knapp-Maloney G; Sunshine H
J Urol; 1990 Dec; 144(6):1393-7; discussion 1397-8. PubMed ID: 1700152
[TBL] [Abstract][Full Text] [Related]
12. Terazosin in the treatment of benign prostatic hyperplasia: the United States experience.
Lepor H; Laddu A
Br J Urol; 1992 Nov; 70 Suppl 1():2-9. PubMed ID: 1281728
[TBL] [Abstract][Full Text] [Related]
13. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
Plosker GL; Goa KL
Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
[TBL] [Abstract][Full Text] [Related]
14. The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group.
Debruyne FM; Witjes WP; Fitzpatrick J; Kirby R; Kirk D; Prezioso D
Eur Urol; 1996; 30(3):369-76. PubMed ID: 8931972
[TBL] [Abstract][Full Text] [Related]
15. WITHDRAWN: Terazosin for benign prostatic hyperplasia.
Wilt TJ; Howe RW; Rutks I; Macdonald R
Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD003851. PubMed ID: 21901686
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of terazosin for the treatment of symptomatic BPH.
Lepor H; Henry D; Laddu AR
Prostate; 1991; 18(4):345-55. PubMed ID: 1711689
[TBL] [Abstract][Full Text] [Related]
17. Effect of terazosin on clinical benign prostatic hyperplasia in older adults.
Mudiyala R; Ahmed A
J Am Geriatr Soc; 2003 Mar; 51(3):424-6. PubMed ID: 12588590
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
[TBL] [Abstract][Full Text] [Related]
19. The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.
Kaplan SA; Te AE; Ikeguchi E; Santarosa RP
Br J Urol; 1997 Dec; 80(6):875-9. PubMed ID: 9439400
[TBL] [Abstract][Full Text] [Related]
20. Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months.
Djavan B; Seitz C; Roehrborn CG; Remzi M; Fakhari M; Waldert M; Basharkhah A; Planz B; Harik M; Marberger M
Urology; 2001 Jan; 57(1):66-70. PubMed ID: 11164146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
